Rapid rise in diabetic population across the globe has considerably increased the demand for effective diabetes management systems. Currently, blood glucose meters are widely used for diabetes management; however, the trend is shifting towards minimally invasive (CGMS) or noninvasive glucose monitoring systems as these systems reduce the need for regular finger pricking and also lessen the pain. Continuous glucose monitoring systems are real time glucose sensing and monitoring devices that measure and display glucose levels of a patient at regular intervals. The usage of CGM is substantially increasing over traditional glucose monitoring systems as these systems are user friendly, provide access to real time values and trend, and provide enhanced accuracy. Additionally, it has been observed that continuous glucose monitoring significantly helps in diabetes management especially in type I diabetics, and helps in reducing long-term complications associated with diabetes. Increasing awareness in developed and developing economies, technological advancements and rising number of diabetic patients are some of the key factors that are expected to fuel the growth of this market.
According to International Diabetes Federation (IDF) reports, approximately 382 million people globally were diagnosed with diabetes in 2013 and this number is expected to grow to 592 million by 2035. Additionally, as per Juvenile Diabetes Research Foundation (JDRF), the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age and is identified as the seventh leading cause of death in the country. Hence, rising number of patients suffering from type I diabetes is likely to increase the demand for CGMS. The continuous glucose monitoring market has been segmented on the basis of various CGM systems available in the market including Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus, Dexcom G4 Platinum and MiniMed Paradigm Revel/Veo CGM Systems. In 2012, the market for Guardian Real Time CGM system held the largest share globally, followed by Dexcom Seven Plus CGM system. However, during the forecast period 2013 to 2019, growth of the market for Guardian Real Time CGM system is expected to be slowest due to market saturation and development of innovative competitor products. Dexcom G4 Platinum CGM System market is expected to witness the fastest growth during the forecast period. FreeStyle Navigator that witnessed a decline in its market share in 2012 due to product recall from the U.S. market is anticipated to show significant growth during the forecast period due to expected launch of FreeStyle Navigator ll in 2014 in the U.S. market.
North America held the largest share in the global continuous glucose monitoring market in terms of revenue in 2012. Factors responsible for the leading position of this region were rising obesity population, aging population and increasing acceptance of technologically advanced devices. Europe held the second largest market in 2012, followed by Asia-Pacific. The Asia-Pacific region is expected to show the highest CAGR during the forecast period because of the presence of growing patient awareness, economic development and changing lifestyle. Other factors such as increasing healthcare expenditure, increasing market penetration by CGM players in this region are anticipated to increase the uptake of these devices in this region.
Medtronic, Inc., Dexcom, Inc., Abbott Diabetes Care, Inc., Bayer AG, Nova Biomedical Corporation, Senseonics, Incorporated, GlySens, Incorporated and Insulet Corporation are the major companies engaged in the development and commercialization of the continuous glucose monitoring systems. Presence of very few players in the CGM market provides ample opportunity for further research and development for both existing and emerging players.
Continuous glucose monitoring systems (CGMS) are real time, portable glucose monitoring systems used for the measurement of glucose levels at regular intervals from the patient’s body. These devices use wireless technology for transmitting glucose readings collected from the interstitial fluid between the patient’s skin cells, unlike blood glucose meters that measure glucose levels in the blood. According to International Diabetes Federation (IDF), approximately 382 million people were diagnosed with diabetes globally in 2013 and this number is expected to grow to 592 million by 2035. Similarly, in the U.K. approximately 10% of the total diabetic population are diagnosed with type I diabetes. Additionally, according to JDRF the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age. Thus, CGMS are identified as one of the most important emerging tools for diabetes management, especially type I diabetes in which patients are completely insulin dependent.
This report on continuous glucose monitoring studies the current scenario as well as the future market potential for continuous glucose monitoring systems (CGMS) globally. The market for these continuous glucose monitoring systems (CGMS) has been segmented by major devices/brands, namely, Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus CGM System, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo System and others. The continuous glucose monitoring systems market for these systems has been extensively analyzed on the basis of factors such as their commercial launch, sales revenue, geographic presence, usage and technological developments. The market size and forecasts in terms of revenue (USD million) for each of above mentioned segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2013 to 2019.
Geographically, the continuous glucose monitoring market has been classified into four segments namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. Porter’s five forces analysis would help determine the degree of competition among the players and the threat from new entrant or substitutes. Furthermore, the report on CGM also includes executive summary, that that will help you understand the overall market size, growth rate of various segments, geographies and competitors present in the market in a very precise manner.
The report on CGM also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global continuous glucose monitoring market (CGM), in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The continuous glucose monitoring market report concludes with the profiles of major players in the global continuous glucose monitoring market such as Medtronic, Inc., Dexcom, Inc., Abbott Laboratories, Inc., Bayer AG, Nova Biomedical Corporation, Senseonics, Incorporated, GlySens, Incorporated and Insulet Corporation. The profiles of these players has been extensively analyzed on the basis of product portfolio, company overview, financial overview, recent developments and business strategies adopted by the companies to ensure sustainability and maximize profits.
The global continuous glucose monitoring market is segmented as follows:
Continuous Glucose Monitoring Market, by Device/Brand
- Guardian Real Time CGM System
- FreeStyle Navigator
- Dexcom Seven Plus CGM System
- Dexcom G4 Platinum
- MiniMed Paradigm Revel/Veo System
Continuous Glucose Monitoring Market, by Geography
- North America
- Rest of the World (RoW)